At what time will the investor presentation for Indivior be available?

The investor presentation will be available on Indivior's investor website at 7:00 am ET.

Who will be hosting the live webcast presentation regarding Indivior's financial results?

Mark Crossley, the CEO of Indivior, will host the live webcast presentation.

On what date did Indivior PLC announce its financial results?

The financial results announcement was made on October 24, 2024.

What is Indivior PLC's mission in the pharmaceutical industry?

Indivior is a global pharmaceutical company dedicated to treating substance use disorders and related conditions.

Indivior Announces Q3 2024 Financial Results

Q: What recent financial results did Indivior PLC announce?

Indivior PLC announced its financial results for the period ending September 30, 2024.

10/24/24 2:00:00 AM ET

$INDV

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $INDV alert in real time by email

SLOUGH, United Kingdom and RICHMOND, Va., Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.

The earnings release can be found at www.indivior.com/investors
The investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)

There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below.

Webcast link: https://edge.media-server.com/mmc/p/ppm4ske8

Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BId4d5b45a6f3e4291ba42150c1620fc64

(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-q3-2024-financial-results-302285061.html

SOURCE Indivior PLC

Get the next $INDV alert in real time by email

Date	Price Target	Rating	Analyst
7/23/2024	$22.00	Overweight	Piper Sandler
4/3/2024	$37.00	Buy	Craig Hallum
7/13/2023	$35.00	Outperform	Northland Capital

Date

Price Target

Rating

Analyst

7/23/2024

$22.00

Overweight

Piper Sandler

4/3/2024

$37.00

Buy

Craig Hallum

7/13/2023

$35.00

Outperform

Northland Capital

Indivior Announces Q3 2024 Financial Results

Chat with this insight

Q&A

What recent financial results did Indivior PLC announce?

At what time will the investor presentation for Indivior be available?

Who will be hosting the live webcast presentation regarding Indivior's financial results?

On what date did Indivior PLC announce its financial results?

What is Indivior PLC's mission in the pharmaceutical industry?

Recent Analyst Ratings for
$INDV

$INDV
Market Insights

Live Market Insights

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Indivior shares are trading higher after the company reported better-than-expected Q2 financial results and announced an accelerated $100 million share repurchase program.

Indivior Expects 2024 Net Revenue Of $1.15B-$1.215B Vs. Consensus Of $1.215B; Adjusted Gross Margin Of Low Mid 80% Range; Adjusted Operating Income Of $285M-$320M

$INDV
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Piper Sandler initiated coverage on Indivior with a new price target

Craig Hallum initiated coverage on Indivior with a new price target

Northland Capital initiated coverage on Indivior with a new price target

$INDV
Press Releases

Fastest customizable press release news feed in the world

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

$INDV
SEC Filings

SEC Form 6-K filed by Indivior PLC

SEC Form 6-K filed by Indivior PLC

SEC Form 6-K filed by Indivior PLC

$INDV
Financials

Live finance-specific insights

$INDV
Large Ownership Changes

This live feed shows all institutional transactions in real time.